For example, multiple therapeutic antibodies that block immune checkpoints, such as cytotoxic T lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1), showed great effects in treating non-small-cell lung cancer, kidney cancer, and melanoma (14). This evidence concerns the gene CTLA4 and kidney cancer.